8 research outputs found
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Recommended from our members
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50-70 days post-auHSCT, followed by the second dose at 1-2 months (M) later. In cohorts of 114-1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18-49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
<p>Abstract</p> <p>Background</p> <p>The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.</p> <p>Methods</p> <p>Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed.</p> <p>Results</p> <p>Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (<it>P</it> = 0.029) and PFS (<it>P</it> = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (<it>P</it> = 0.021) and PFS (<it>P <</it>0.001).</p> <p>Conclusions</p> <p>Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value.</p
Effect of recombinant zoster vaccine on incidence of Herpes zoster after autologous stem cell transplantation : a randomized clinical trial
IMPORTANCE Herpes zoster, a frequent complication following autologous hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. A nonlive adjuvanted recombinant zoster vaccine has been developed to prevent posttransplantation zoster.
OBJECTIVE To assess the efficacy and adverse event profile of the recombinant zoster vaccine in immunocompromised autologous HSCT recipients.
DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded study conducted in 167 centers in 28 countries between July 13, 2012, and February 1, 2017, among 1846 patients aged 18 years or older who had undergone recent autologous HSCT.
INTERVENTIONS Participants were randomized to receive 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) administered into the deltoid muscle; the first dose was given 50 to 70 days after transplantation and the second dose 1 to 2 months thereafter.
MAIN OUTCOMES AND MEASURES The primary end point was occurrence of confirmed herpes zoster cases.
RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688 [37%] women) who received 1 vaccine or placebo dose, 1735 (94%) received a second dose and 1366 (74%) completed the study. During the 21-month median follow-up, at least 1 herpes zoster episode was confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94 per 1000 person-years, respectively), an incidence rate ratio (IRR) of 0.32 (95% CI, 0.22-0.44; P<.001), equivalent to 68.2% vaccine efficacy. Of 8 secondary end points, 3 showed significant reductions in incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR, 0.1; 95% CI, 0.00-0.78; P=.02) and of other prespecified herpes zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22; 95% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days; hazard ratio, 0.62; 95% CI, 0.42-0.89; P=.01). Five secondary objectives were descriptive. Injection site reactions were recorded in 86% of vaccine and 10% of placebo recipients, of which pain was the most common, occurring in 84% of vaccine recipients (grade 3: 11%). Unsolicited and serious adverse events, potentially immune-mediated diseases, and underlying disease relapses were similar between groups at all time points.
CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine compared with placebo significantly reduced the incidence of herpes zoster over a median follow-up of 21 months.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
IMPORTANCE Herpes zoster, a frequent complication following autologous
hematopoietic stem cell transplantation (HSCT), is associated with
significant morbidity. A nonlive adjuvanted recombinant zoster vaccine
has been developed to prevent posttransplantation zoster.
OBJECTIVE To assess the efficacy and adverse event profile of the
recombinant zoster vaccine in immunocompromised autologous HSCT
recipients.
DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded
study conducted in 167 centers in 28 countries between July 13, 2012,
and February 1, 2017, among 1846 patients aged 18 years or older who had
undergone recent autologous HSCT.
INTERVENTIONS Participants were randomized to receive 2 doses of either
recombinant zoster vaccine (n=922) or placebo (n=924) administered into
the deltoid muscle; the first dose was given 50 to 70 days after
transplantation and the second dose 1 to 2 months thereafter.
MAIN OUTCOMES AND MEASURES The primary end point was occurrence of
confirmed herpes zoster cases.
RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688
[37%] women) who received 1 vaccine or placebo dose, 1735 (94%)
received a second dose and 1366 (74%) completed the study. During the
21-month median follow-up, at least 1 herpes zoster episode was
confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94
per 1000 person-years, respectively), an incidence rate ratio (IRR) of
0.32 (95% CI, 0.22-0.44; P<.001), equivalent to 68.2% vaccine
efficacy. Of 8 secondary end points, 3 showed significant reductions in
incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR,
0.1; 95% CI, 0.00-0.78; P=.02) and of other prespecified herpes
zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22;
95% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes
zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days;
hazard ratio, 0.62; 95% CI, 0.42-0.89; P=.01). Five secondary
objectives were descriptive. Injection site reactions were recorded in
86% of vaccine and 10% of placebo recipients, of which pain was the
most common, occurring in 84% of vaccine recipients (grade 3: 11%).
Unsolicited and serious adverse events, potentially immune-mediated
diseases, and underlying disease relapses were similar between groups at
all time points.
CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous
HSCT, a 2-dose course of recombinant zoster vaccine compared with
placebo significantly reduced the incidence of herpes zoster over a
median follow-up of 21 months.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
IMPORTANCE Herpes zoster, a frequent complication following autologous
hematopoietic stem cell transplantation (HSCT), is associated with
significant morbidity. A nonlive adjuvanted recombinant zoster vaccine
has been developed to prevent posttransplantation zoster.
OBJECTIVE To assess the efficacy and adverse event profile of the
recombinant zoster vaccine in immunocompromised autologous HSCT
recipients.
DESIGN, SETTING, AND PARTICIPANTS Phase 3, randomized, observer-blinded
study conducted in 167 centers in 28 countries between July 13, 2012,
and February 1, 2017, among 1846 patients aged 18 years or older who had
undergone recent autologous HSCT.
INTERVENTIONS Participants were randomized to receive 2 doses of either
recombinant zoster vaccine (n=922) or placebo (n=924) administered into
the deltoid muscle; the first dose was given 50 to 70 days after
transplantation and the second dose 1 to 2 months thereafter.
MAIN OUTCOMES AND MEASURES The primary end point was occurrence of
confirmed herpes zoster cases.
RESULTS Among 1846 autologous HSCT recipients (mean age, 55 years; 688
{[}37\%] women) who received 1 vaccine or placebo dose, 1735 (94\%)
received a second dose and 1366 (74\%) completed the study. During the
21-month median follow-up, at least 1 herpes zoster episode was
confirmed in 49 vaccine and 135 placebo recipients (incidence, 30 and 94
per 1000 person-years, respectively), an incidence rate ratio (IRR) of
0.32 (95\% CI, 0.22-0.44; P<.001), equivalent to 68.2\% vaccine
efficacy. Of 8 secondary end points, 3 showed significant reductions in
incidence of postherpetic neuralgia (vaccine, n=1; placebo, n=9; IRR,
0.1; 95\% CI, 0.00-0.78; P=.02) and of other prespecified herpes
zoster-related complications (vaccine, n=3; placebo, n=13; IRR, 0.22;
95\% CI, 0.04-0.81; P=.02) and in duration of severe worst herpes
zoster-associated pain (vaccine, 892.0 days; placebo, 6275.0 days;
hazard ratio, 0.62; 95\% CI, 0.42-0.89; P=.01). Five secondary
objectives were descriptive. Injection site reactions were recorded in
86\% of vaccine and 10\% of placebo recipients, of which pain was the
most common, occurring in 84\% of vaccine recipients (grade 3: 11\%).
Unsolicited and serious adverse events, potentially immune-mediated
diseases, and underlying disease relapses were similar between groups at
all time points.
CONCLUSIONS AND RELEVANCE Among adults who had undergone autologous
HSCT, a 2-dose course of recombinant zoster vaccine compared with
placebo significantly reduced the incidence of herpes zoster over a
median follow-up of 21 months.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0161041